Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
2020; American Association for the Advancement of Science; Volume: 369; Issue: 6510 Linguagem: Inglês
10.1126/science.abc5881
ISSN1095-9203
AutoresZhe Lv, Yong‐Qiang Deng, Qing Ye, Lei Cao, Chun-Yun Sun, Changfa Fan, Weijin Huang, Shihui Sun, Yao Sun, Ling Zhu, Qi Chen, Nan Wang, Jianhui Nie, Zhen Cui, Dandan Zhu, Neil Shaw, Xiao-Feng Li, Qianqian Li, Liangzhi Xie, Youchun Wang, Zihe Rao, Cheng‐Feng Qin, Xiangxi Wang,
Tópico(s)COVID-19 Clinical Research Studies
ResumoA steric block to SARS-CoV-2 In response to infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the immune system makes antibodies, many of which target the spike protein, a key player in host cell entry. Antibodies that potently neutralize the virus hold promise as therapeutics and could inform vaccine design. Lv et al. report a humanized monoclonal antibody that protected against SARS-CoV-2 in a mouse model. The cryo–electron microscopy structure, together with biochemical, cellular, and virological studies, showed that the antibody acts by binding to the receptor-binding domain of the spike and blocking its attachment to the host receptor. Science , this issue p. 1505
Referência(s)